MRI Interventions, Inc. Announces Agreement to Restructure Brainlab AG Senior Secured Note Agreement Includes an Equity Investment, License Agreement, Restructured Note and Interest Payment

MRI Interventions, Inc. Announces Agreement

Restructure Brainlab AG Senior Secured Note

Includes an Equity Investment, License Agreement,

Restructured Note and Interest Payment

March 22, 2016 (GLOBE NEWSWIRE) - MRI Interventions, Inc. (OTCQB: MRIC) today announced it has reached a definitive agreement

with Brainlab AG to restate and restructure the Amended and Restated Secured Note issued by MRIC to Brainlab on March 6, 2013,

effective April 4, 2016.

very pleased to reach this agreement with Brainlab," commented Frank Grillo, President and CEO of MRI Interventions.

"This is a very positive step for MRIC, and it is great to have Brainlab as a shareholder committed to the success of our

platform. Brainlab is taking a significant step with us - as an equity investor, a note holder, a licensee and a customer.

We appreciate their investment in us as well as their commitment to the growth of our technology."

agreement, MRI Interventions and Brainlab have agreed to restate and restructure the Amended and Restated Secured Note issued on

March 6, 2013, including the principal of $4,289,444 and accrued interest of $739,323, for a total value of $5,028,767 (the "March

2013 Note"), as follows:

California 92618 949.900.6833

ClearPoint system allows surgeons to plan, target, and adjust trajectories under continuous real time MRI-guided visualization

for placement of electrodes, catheters and biopsy needles. Since it received clearance from the U.S. Food and Drug Administration

(FDA) in 2010, the ClearPoint system has been adopted for use in more than 40 leading institutions across the country. MRI Interventions

provides ongoing technical support to these medical institutions after the installation of the ClearPoint system.

About MRI Interventions, Inc.

Building on the imaging power of magnetic

resonance imaging, or MRI, MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive

surgical procedures in the brain and heart. The Company's ClearPoint System, which has received 510(k) clearance and

is CE marked, utilizes a hospital's existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive

procedures in the brain. In partnership with Siemens Healthcare, MRI Interventions is developing the ClearTrace System to

enable MRI-guided catheter ablations to treat cardiac arrhythmias. For more information, please visit www.mriinterventions.com.

Forward-Looking Statements

Statements herein concerning the Company's

plans, growth and strategies may include forward-looking statements' within the context of the federal securities laws. Statements

regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans,

estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's

actual results may differ materially from those suggested as a result of various factors. Particular uncertainties and risks include

those relating to: estimates regarding the sufficiency of the Company's cash resources; the Company's ability to obtain

additional financing; future revenues from sales of the Company's ClearPoint System products; and the Company's ability

to market, commercialize and achieve broader market acceptance for the Company's ClearPoint System products. More detailed

information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors"

sections of the Company's Form 10-K for the year ended December 31, 2014 and the Company's Form 10-Q for the quarter ended

September 30, 2015, both of which have been filed with the Securities and Exchange Commission, as well as the Company's Form 10-K

for the year ended December 31, 2015, which will be filed with the Securities and Exchange Commission.